Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

NCT02501928 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Neurogenic

Interventions

DRUG: Fesoterodine PR 4 mg
DRUG: Fesoterodine PR 8 mg
DRUG: Fesoterodine BIC 2 mg
DRUG: Fesoterodine BIC 4 mg

Sponsor

Pfizer